Dermatological complications and safety of anti-TNF treatments

Gut

Volumn 58, Issue 8, 2009, Pages 1033-1039

  Kerbleski, Joseph F ^a   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABSCESS; ALLERGIC RASH; ALOPECIA; ANKYLOSING SPONDYLITIS; BRONCHOSPASM; CELLULITIS; CHICKENPOX; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CROHN DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; ENTERITIS; ERYSIPELAS; ERYTHEMA; ERYTHEMA MULTIFORME; FEVER; FLUSHING; FOLLICULITIS; FOOD AND DRUG ADMINISTRATION; GINGIVITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPOTENSION; INFECTION RISK; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LARYNX EDEMA; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; MOLLUSCUM CONTAGIOSUM; MOUTH EDEMA; MOUTH ULCER; NONHUMAN; PARONYCHIA; PHARYNGEAL EDEMA; PHARYNGITIS; PHARYNX DISEASE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SARCOIDOSIS; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN LYMPHOMA; SKIN MANIFESTATION; SKIN ULCER; SKIN VASCULITIS; STEVENS JOHNSON SYNDROME; SURGICAL INFECTION; TONGUE DISEASE; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS; URTICARIA; VARICELLA ZOSTER VIRUS; VASCULITIS;

ANTIRHEUMATIC AGENTS; DRUG ERUPTIONS; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OPPORTUNISTIC INFECTIONS; PSORIASIS; SKIN DISEASES, INFECTIOUS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650227459     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.163683     Document Type: Review

References (44)

1. Product websites. As found on product websites and confirmed with companies: http://www.humira. com/, http://www.enbrel.com/?channel= GOSEA&subchannel=SENC, http://www.remicade. com/remicade/global/index.html, and http://www. cimzia.com/Default1.asp (all websites accessed 1 November 2008)
2. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
3. Lee HH, Song IH, Friedrich M, et al. Cutaneous sideeffects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-91.
4. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab, http://www.fda.gov/cder/ foi/label/2007/103772s5189lbl.pdf; adalimumab, http://www.fda.gov/cder/foi/label/2008/ 125057s114lbl.pdf; etanercept, http://www.fda.gov/ cder/foi/label/2008/103795s5359lbl.pdf; and certolizumab pegol, http://www.cimzia.com/pdf/ CIMZIA%20PI%20032008.pdf (all websites accessed 1 November 2008)
5. US Food and Drug Administration. FDA prescribing information: etanercept http://www.fda.gov/cder/foi/ label/2002/etanimm091202PLB.pdf; adalimumab http://www.fda.gov/Cder/foi/label/2002/ adalabb123102LB.htm (websites accessed 1 November 2008)
6. Centecor Inc. Centecor data. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors.
7. Moss AC, Fernandez-Becker N, Jo Kim K, et al. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:221-7.
8. Lees CW, Ali A, Thompson A, et al. The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29:286- 97.
9. Figueiredo IT, Morel J, Sany J, et al. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:18-23.
10. Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006;8:R131.
11. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
12. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
13. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:647-9.
14. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
15. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
16. Zelinger DJ, Stang PE, Lane CE, et al. Long-term follow-up of rheumatologic patients receiving infliximab demonstrates low rates of discontinuation: a retrospective chart review [poster]. European League Against Rheumatism, 21-24 June 2006. Amsterdam, Netherlands. Poster SAT0208 Ref 16:
17. Lequerré T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006;33:1307-14.
18. Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004;31:1912-7.
19. Sany J, Kaiser MJ, Jorgensen C, et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:1647-9.
20. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
21. Cabou C, Bagheri H, Cantagrel A, et al. Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service. Therapie 2003;58:457-62.
22. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
23. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-21
24. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
25. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159:1217-28.
26. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
27. Crum NF, Lederman ER, Wallace MR, et al. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.
28. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30.
29. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
30. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689-95.
31. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7.
32. Hernandez C, Emer J, Robinson JK. Perioperative management of medications for psoriasis and psoriatic arthritis: a review for the dermasurgeon. Dermatol Surg 2008;34:446-59.
33. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions. J Rheumatology 2007;34:653-5.
34. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF blockade therapy: A review and analysis of 127 cases. J Dermatol Treatment 2009;20:100-8.
35. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept. Clin Infect Dis 2005;41:S199-S203.
36. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10:202.
37. Ramos-Casals M, Brito-Zerón P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61.
38. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
39. Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-6
40. Klapman JB, Ene-Stroescu D, Becker MA, et al. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003;9:176-8
41. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004;50:1690-2.
42. Kain T, MacGregor D, Buchanan RR, et al. Erythema multiforme with tumour necrosis factor inhibitors: a class effect? Ann Rheum Dis 2008;67:899-900.
43. US Food and Drug Administration. Tumor Necrosis Factor alpha (TNF-α) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: Serious Skin Reactions. FDA Drug Safety Newsletter 2008;1(2). http://www.fda.gov/cder/ dsn/ 2008-winter/postmarketing.htm#tnf (accessed 15 December 2008).
44. Jorizzo JL, Daniels JC. Dermatologic conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol 1983;8:439-57.